In this model, CCR2 antagonist treatment in combination with anti‐PD1 antibody suppresses tumour growth, whereas single treatment with anti‐PD1 antibody is not effective.39 Therefore, it is likely that blockade of CCR2 signalling prevents TAM accumulation in the tumour and thereby enhances the efficacy of immune checkpoint inhibition. The gene discussed is CCR2; the disease is neoplasm.